James Orrell, MD
General Practice · Marion, INNPI 1447220900
Payments from drug & device makers
Across 150 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$825
- Bayer$777
- AstraZeneca$230
- Novo Nordisk$207
- Biohaven Pharmaceuticals, Inc.$107
- Phathom Pharmaceuticals, Inc.$78
- plus $386 from 13 others
What the payments were for
- Food & beverage$2,603100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $825 |
| Bayer | 37 | $777 |
| AstraZeneca | 8 | $230 |
| Novo Nordisk | 7 | $207 |
| Biohaven Pharmaceuticals, Inc. | 1 | $107 |
| Phathom Pharmaceuticals, Inc. | 1 | $78 |
| Boston Scientific | 1 | $69 |
| Amgen | 1 | $67 |
| GSK | 3 | $40 |
| Exact Sciences | 2 | $35 |
| Alkermes, Inc. | 2 | $33 |
| Novartis | 2 | $31 |
| Lilly USA, LLC | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $14 |
| Pfizer | 1 | $14 |
| Corium, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$480
- UBRELVY$125
- VRAYLAR$125
- Ozempic$122
- NURTEC ODT$107
How this compares
$2,609 in reported general payments places this provider in the 90th percentile of 1,558 general practice providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 401 | $548,641 |
| OzempicSemaglutide | 202 | $321,420 |
| JardianceEmpagliflozin | 200 | $281,360 |
| FarxigaDapagliflozin Propanediol | 106 | $141,420 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $104,794 |
| JanuviaSitagliptin Phosphate | 56 | $82,239 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $74,872 |
| XareltoRivaroxaban | 49 | $56,265 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $53,798 |
| MounjaroTirzepatide | 46 | $53,301 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $45,367 |
| EntrestoSacubitril/Valsartan | 24 | $39,407 |
| TrulicityDulaglutide | 24 | $38,818 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $31,425 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 11 | $31,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $548,641401 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $207 | $380,745229 claims |
| AstraZenecaFarxiga, Symbicort | $230 | $150,671132 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $40 | $118,326114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $22 | $92,11970 claims |
| NovartisEntresto | $31 | $39,40724 claims |
| AbbVieVraylar | $825 | $27,33017 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $24,99323 claims |
| BayerKerendia | $777 | $18,38514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,558 general practice providers in Indiana.
Other general practice in Marion
- Tina GermanWarsaw$260K
- Kenneth TroutmanHuntingburg$124K
- Roger JonesClinton$78K
- Daniel KlauerGranger$45K
- William FloraElkhart$39K
- Ryan HolmesFort Wayne$33K
- Samuel CoreyFort Wayne$27K
- Kara WulffMuncie$23K
- Gary WalkerFishers$19K
- Adam HubertEvansville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.